Several other research firms have also issued reports on VIVE. Mizuho lowered shares of Viveve Medical from a “buy” rating to an “underperform” rating and reduced their target price for the stock from $4.00 to $0.20 in a report on Tuesday, July 23rd. Stifel Nicolaus lowered shares of Viveve Medical from a “buy” rating to a “hold” rating and reduced their target price for the stock from $3.00 to $1.00 in a report on Monday, July 22nd. Raymond James lowered shares of Viveve Medical from an “outperform” rating to a “market perform” rating in a report on Tuesday, July 23rd. Maxim Group reissued a “hold” rating on shares of Viveve Medical in a report on Friday, August 9th. Finally, LADENBURG THALM/SH SH lowered shares of Viveve Medical from a “buy” rating to a “neutral” rating in a report on Wednesday, July 24th. One investment analyst has rated the stock with a sell rating and six have assigned a hold rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $2.24.
NASDAQ VIVE opened at $5.01 on Friday. Viveve Medical has a 52 week low of $4.66 and a 52 week high of $371.00. The company has a quick ratio of 2.30, a current ratio of 2.98 and a debt-to-equity ratio of 6.21. The company has a 50-day moving average price of $1.15 and a 200-day moving average price of $0.69.
Viveve Medical (NASDAQ:VIVE) last released its quarterly earnings results on Thursday, August 8th. The company reported ($21.00) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($18.00) by ($3.00). The business had revenue of $1.05 million for the quarter, compared to analysts’ expectations of $3.92 million. Viveve Medical had a negative net margin of 341.01% and a negative return on equity of 2,976.15%. On average, equities analysts predict that Viveve Medical will post -69 EPS for the current fiscal year.
An institutional investor recently raised its position in Viveve Medical stock. Meitav Dash Investments Ltd. grew its position in shares of Viveve Medical Inc (NASDAQ:VIVE) by 30.1% in the first quarter, according to its most recent filing with the SEC. The fund owned 988,573 shares of the company’s stock after acquiring an additional 228,517 shares during the quarter. Meitav Dash Investments Ltd. owned about 2.13% of Viveve Medical worth $955,000 at the end of the most recent reporting period. 44.29% of the stock is currently owned by institutional investors and hedge funds.
About Viveve Medical
Viveve Medical, Inc designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable components.
Featured Article: Treasury Bonds
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.